Monitoring Conformational Changes in the Receptor Tyrosine Kinase EGFR

被引:1
|
作者
Becker, Christian [1 ]
Oecal, Sinan [2 ,3 ]
Nguyen, Hoang D. [2 ,4 ]
Trang Phan [2 ,4 ]
Keul, Marina [1 ]
Simard, Jeffrey R. [2 ,5 ]
Rauh, Daniel [1 ,2 ]
机构
[1] Tech Univ Dortmund, Fak Chem & Chem Biol, Otto Hahn Str 4a, D-44227 Dortmund, Germany
[2] Max Planck Inst Mol Physiol, Chem Genom Ctr, Otto Hahn Str 15, D-44227 Dortmund, Germany
[3] Univ Cologne, Dept Math & Nat Sci, Inst Biochem, Otto Fischer Str 12-14, D-50674 Cologne, Germany
[4] Vietnam Natl Univ Ho Chi Minh City, Univ Sci, 227 Nguyen van Cu Str Dist 5, Ho Chi Minh City, Vietnam
[5] Amgen Inc, 360 Binney St, Cambridge, MA 02142 USA
关键词
GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; INHIBITOR SELECTIVITY; DRUG-RESISTANCE; MUTATIONS; GEFITINIB; DOMAIN; ERLOTINIB; AZD9291; ACTIVATION;
D O I
10.1002/cbic.201600115
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The receptor tyrosine kinase EGFR is regulated by complex conformational changes, and this conformational control is disturbed in certain types of cancer. Many ligands are known to bind EGFR in its active conformation, thereby preventing ATP from binding. Only a few ligands are known to stabilize EGFR in its inactive conformation, thus providing novel strategies for perturbing EGFR activity. We report a direct binding assay that enables the identification of novel ligands that bind to and stabilize the inactive conformation of EGFR.
引用
收藏
页码:990 / 994
页数:5
相关论文
共 50 条
  • [21] Mutation and drug-specific intracellular accumulation of EGFR predict clinical responses to tyrosine kinase inhibitors
    de Wit, Maurice
    Gao, Ya
    Mercieca, Darlene
    de Heer, Iris
    Valkenburg, Bart
    van Royen, Martin E.
    Aerts, Joachim
    Smitt, Peter Sillevis
    French, Pim
    EBIOMEDICINE, 2020, 56
  • [22] Quantification of epidermal growth factor receptor (EGFR) mutation may be a predictor of EGFR-tyrosine kinase inhibitor treatment response
    Park, Ha Young
    Oh, Hyung Joo
    Kim, Ki-Hyun
    Kim, Tae-Ok
    Park, Cheol-Kyu
    Shin, Hong-Jun
    Lim, Jung-Hwan
    Kwon, Yong-Soo
    Oh, In-Jae
    Kim, Yu-Il
    Lim, Sung-Chul
    Kim, Young-Chul
    Choi, Yoo-Duk
    THORACIC CANCER, 2016, 7 (06) : 639 - 647
  • [23] EGFR tyrosine kinase inhibitors and multidrug resistance: perspectives
    Colabufo, Nicola A.
    Contino, Marialessandra
    Niso, Mauro
    Berardi, Francesco
    Leopoldo, Marcello
    Perrone, Roberto
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2011, 16 : 1811 - 1823
  • [24] Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain
    Park, Jin H.
    Liu, Yingting
    Lemmon, Mark A.
    Radhakrishnan, Ravi
    BIOCHEMICAL JOURNAL, 2012, 448 : 417 - 423
  • [25] RECIST 1.1 in NSCLC Patients With EGFR Mutations Treated With EGFR Tyrosine Kinase Inhibitors: Comparison With RECIST 1.0
    Nishino, Mizuki
    Cardarella, Stephanie
    Jackman, David M.
    Ramaiya, Nikhil H.
    Rabin, Michael S.
    Hatabu, Hiroto
    Jaenne, Pasi A.
    Johnson, Bruce E.
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2013, 201 (01) : W64 - W71
  • [26] The Effect of Acquired Cisplatin Resistance on Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR Mutant Lung Cancer Cells
    Rho, Jin Kyung
    Choi, Yun Jung
    Choi, You Ri
    Kim, Sun Ye
    Choi, Su Jin
    Choi, Chang-Min
    Na, Im Il
    Lee, Jae Cheol
    ONCOLOGY RESEARCH, 2011, 19 (10-11) : 471 - 478
  • [27] Coexpression of receptor tyrosine kinase AXL and EGFR in human primary lung adenocarcinomas
    Wu, Zhenzhou
    Bai, Fan
    Fan, Liyun
    Pang, Wenshuai
    Han, Ruiyu
    Wang, Juan
    Liu, Yueping
    Yan, Xia
    Duan, Huijun
    Xing, Lingxiao
    HUMAN PATHOLOGY, 2015, 46 (12) : 1935 - 1944
  • [28] Significant increase in hEGF uptake is correlated with formation of EGFR dimers induced by the EGFR tyrosine kinase inhibitor gefitinib
    He, Peng
    Li, Gang
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (02) : 341 - 348
  • [29] The influence of intracellular epidermal growth factor receptor (EGFR) signal activation on the outcome of EGFR tyrosine kinase inhibitor treatment for pulmonary adenocarcinoma
    Kawano, Daigo
    Yano, Tokujiro
    Shoji, Fumihiro
    Ito, Kensaku
    Morodomi, Yosuke
    Haro, Akira
    Miura, Naoko
    Takenaka, Tomoyoshi
    Yoshino, Ichiro
    Maehara, Yoshihiko
    SURGERY TODAY, 2011, 41 (06) : 818 - 823
  • [30] Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors
    Nishino, Mizuki
    Cardarella, Stephanie
    Dahlberg, Suzanne E.
    Jackman, David M.
    Ramaiya, Nikhil H.
    Hatabu, Hiroto
    Rabin, Michael S.
    Jaenne, Pasi A.
    Johnson, Bruce E.
    LUNG CANCER, 2013, 79 (03) : 283 - 288